Scientific Publications
Filter:
Home Optical Coherence Tomography Imaging for Newly Diagnosed Neovascular Age-Related Macular Degeneration: A Feasibility Study
Blinder KJ, Calhoun C, Maguire MG, Glassman AR, Mein CE, Baskin DE, Vieyra G, Jampol LM, Chica MA, Sun JK, Martin DF; DRCR Retina Network. Home Optical Coherence Tomography Imaging for Newly Diagnosed Neovascular Age-Related Macular Degeneration: A Feasibility Study. Ophthalmol Retina. 2023 Oct 23:S2468-6530(23)00514-6. doi: 10.1016/j.oret.2023.10.012. Epub ahead of print. PMID: 37879537. https://pubmed.ncbi.nlm.nih.go...
The Impact of Artificial Intelligence on Retinal Disease Management
Carla Danese; Aditya U. Kale; Tariq Aslam; Paolo Lanzetta; Jane Barratt; Yu-Bai Chou; Bora Eldem; Nicole Eter; Richard Gale; Jean-François Korobelnik; Igor Kozak; Xiaorong Li; Xiaoxin Li; Anat Loewenstein; Paisan Ruamviboonsuk; Taiji Sakamoto; Daniel S.W. Ting; Peter van Wijngaarden; Sebastian M. Waldstein; David Wong; Lihteh Wu; Miguel A. Zapata; Javier Zarranz-Ventura. DISCLOSURES | Curr Opin Ophthalmol. 2023;34(5):396-402. https://www.medscape.com/s/vie...
The Impact of Artificial Intelligence on Retinal Disease Management: Vision Academy Retinal Expert Consensus
Danese, Carla; Kale, Aditya U.; Aslam, Tariq; Lanzetta, Paolo; Barratt, Jane; Chou, Yu-Bai; Eldem, Bora; Eter, Nicole; Gale, Richard; Korobelnik, Jean-François; Kozak, Igor; Li, Xiaorong; Li, Xiaoxin; Loewenstein, Anat; Ruamviboonsuk, Paisan; Sakamoto, Taiji; Ting, Daniel S.W.; van Wijngaarden, Peter; Waldstein, Sebastian M.; Wong, David; Wu, Lihteh; Zapata, Miguel A.; Zarranz-Ventura, Javier. The Impact of Artificial Intelligence on Retinal Disease Management: Vision Academy Retinal Expert ConsensusCurrent Opinion in Ophthalmology, September 2023 | DOI: 10.1097/ICU.0000000000000980
Artificial Intelligence for Home Monitoring Devices
Keenan, Tiarnan D.L.; Loewenstein, Anat. Artificial intelligence for home monitoring devices. Current Opinion in Ophthalmology ():10.1097/ICU.0000000000000981, June 20, 2023. | DOI: 10.1097/ICU.0000000000000981
SCANLY Home OCT FDA Intended Use
SCANLY Home OCT has not been approved by FDA for use other than described in the following Intend Use: The Notal Vision Home Optical Coherence Tomography (OCT) System is an Artificial Intelligence (AI)-based Home Use device indicated for visualization of intraretinal and subretinal hypo-reflective spaces in a 10 by 10-degrees area centered on the point of fixation of eyes diagnosed with neovascular age-related macular degeneration (NV-AMD). In addition, it provides segmentation and an estimation of the volume of hypo-reflective spaces. The Notal Home OCT device is intended for imaging at home between regularly scheduled clinic assessments and not intended to be used to make treatment decisions or replace standard-of care regularly scheduled examinations and clinical testing as needed, including in-office imaging and assessments for changes in vision, by an ophthalmologist.
See also Warnings and Precautions.
ForeseeHome FDA Intended Use
ForeseeHome has not been approved by FDA for use other than described in the following Indication for Use: The ForeseeHome is intended for use in the detection and characterization of central and paracentral metamorphopsia (visual distortion) in patients with age-related macular degeneration as an aid in monitoring progression of disease factors causing metamorphopsia including, but not limited to choroidal neovascularization (CNV). It is intended to be used at home for patients with stable fixation.
